New Methylation Biomarker Panel for Early Diagnosis of Dysplasia or Cancer in High-Risk Inflammatory Bowel Disease Patients-Reference-Cited by-同舟云学术

New Methylation Biomarker Panel for Early Diagnosis of Dysplasia or Cancer in High-Risk Inflammatory Bowel Disease Patients

Published:2018-08-07 Issue: Volume: Page:
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Azuara Daniel¹,Aussó Susanna²,Rodriguez-Moranta Francisco³,Guardiola Jordi³,Sanjuan Xavier⁴,Lobaton Triana⁵,Boadas Jaume⁶,Piqueras Marta⁶,Monfort David⁶,Guinó Elisabet²,Moreno Victor²,Capellá Gabriel¹,de Oca Javier⁷

Affiliation:

1. Translational Research Laboratory, Catalan Insitute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L′Hospitalet de Llobregat, Barcelona, Spain

2. Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, ICO–IDIBELL and CIBERESP, L′Hospitalet de Llobregat, Barcelona, Spain

3. Department of Gastroenterology, University Hospital Bellvitge (HUB-IDIBELL), L′Hospitalet de Llobregat, Barcelona, Spain

4. Department of Pathology, University Hospital Bellvitge (HUB-IDIBELL), L′Hospitalet de Llobregat, Barcelona, Spain

5. Department of Gastroenterology, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain

6. Department of Gastroenterology, Hospital of Terrassa, Terrassa Health Consortium (CST), Terrassa, Barcelona, Spain

7. Department of General and Digestive Surgery, Colorectal Unit, University Hospital Bellvitge (HUB-IDIBELL)-CIBERONC, L′Hospitalet de Llobregat, Barcelona, Spain

Funder

Instituto de Salud Carlos III

Ministerio de Economía y Competitividad

Fondo Europeo de Desarrollo Regional

Catalan Health Institute and Autonomous Government of Catalonia DURSI

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/advance-article-pdf/doi/10.1093/ibd/izy255/25448384/izy255.pdf

Reference44 articles.